Please login to the form below

Not currently logged in
Email:
Password:

Shire's Q3 net profit doubles

Net profit for Shire recovers from payment to Acceleron and impairment charges relating to the divestment of Daytrana

Shire has recorded a net profit of $192.9m for the third quarter of 2011 – an increase from 2010 of 100 per cent.

Last year, the Ireland-based pharmaceutical company made $96.3m after being hit by payments to Acceleron Pharma and impairment charges related to the divestment of ADHD treatment Daytrana (methylphenidate).

Discounting the one-off charges, as well as other measures specified by the company, net profit was still up, increasing from $220.3m in 2010 to $244.7m in 2011.

This was bolstered by a strong sales performance, with total revenues for Shire increasing 24 per cent to $1.09bn.

Products that performed particularly well in the quarter included ADHD treatments Vyvanse (lisdexamfetamine) and Adderall XR (amphetamine, dextroamphetamine mixed salts).

Vyvanse made $199.7m, an increase in sales of 32 per cent, while Adderall XR made $149.9m, an increase of 50 per cent.

Angus Russell, CEO of Shire, said: "The investment in our product portfolio is already delivering benefits and we believe our R&D pipeline will provide important therapies to patients around the world.

"Overall, we've increased investment in our R&D programmes by 21 per cent compared to Q3 2010, and still generated good earnings growth and strong cashflows."

31st October 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...